Article
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Oncotarget - 22 Sept 2015
Fattore Luigi, Malpicci Debora, Marra Emanuele, Belleudi Francesca, Noto Alessia, De Vitis Claudia, Pisanu Maria Elena, Coluccia Pierpaolo, Camerlingo Rosa, Roscilli Giuseppe, Ribas Antoni, Di Napoli Arianna, Torrisi Maria Rosaria, Aurisicchio Luigi, Ascierto Paolo Antonio, Mancini Rita, Ciliberto Gennaro
Abstract excerpt
Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically benefit from the treatment with BRAF inhibitors alone or in combination with MEK inhibitors. However, a limitation to such treatment is the occurrence of resistance. Tackling the adaptive changes helping cells survive from drug treatment may offer new therapeutic opportunities. Very recently the ErbB3 receptor has been shown to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.